One of the largest, broadest and deepest pipelines of any technology-enabled drug discovery company.

Every program at Recursion is a product of our Recursion OS. With every new discovery, our platform gets smarter, leading to pipeline growth.

Our programs target diseases spanning several therapeutic areas where:


1. the cause of the disease is well-defined

2. there is high unmet need, there are no approved therapies, or there are significant shortcomings with existing treatment paradigms

Phase 1

Familial Adenomatous Polyposis

GM2 Gangliosidosis

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

Preclinical

Clostridium difficile Colitis

Immune checkpoint resistance in STK11-mutant NSCLC

Late Discovery

Neuroinflammation

Batten Disease

Charcot-Marie-Tooth Disease

Oncology
(small molecule
MYC Inhibitors)

Early Discovery

+ 25 programs from early discovery through preclinical

Phase 2
Phase 3
Commercial
Disease Model
Early Discovery
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

GM2 Gangliosidosis

Solid Tumors

Dilated Cardiomyopathy

Clostridium difficile Colitis

Neuroinflammation

Batten Disease

Charcot-Marie-Tooth Disease

Pulmonary Arterial Hypertension

Lung Disease

Senescence

Vascular Disease

+ 18 early
discovery programs

Oncology 1

Oncology 2

Phase 1

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

GM2 Gangliosidosis

*Undisclosed indication

Disease Indication
Early Discovery
Late Discovery
Preclinical
Phase 1
Phase 2
Commercial
Familial Adenomatous Polyposis
GM2 Gangliosidosis
Neurofibromatosis Type 2
Cerebral Cavernous Malformation
Clostridium difficile Colitis
Neuroinflammation
Batten Disease
Charcot-Marie-Tooth Disease
Immune checkpoint resistance in STK11-mutant NSCLC
Oncology
(small molecule 
MYC Inhibitors)
25 programs from early discovery through preclinical
18

Early Discovery

Metabolic Disorders
Tumor Suppression
Cancers
Mitochondrial Diseases
Lysosomal Storage Disorders
Nervous System Disorders
Neurodevelopment Disorders
Neurodegenerative Disorders
Inflammation

4

Discovery

Lung Disease
Senescence
Vascular Dysplasia
Tumor Suppression

6

Preclinical

Dialated Cardiomyophathy
Clostridium Difficile Colitis
Amitrophic Lateral Sclerosis
Batten Disease
Charcot-Marie-Tooth Disease
Pulmonary Arterial Hypertension

3

Phase 1

Neurofibromatosis Type 2
Cerebral Cavernous Malformation
*Undisclosed indication

Welcome to the era of industrialized drug discovery.

Proud founding member of BioHive, the fastest growing life sciences community in the nation

Get In Touch

41 S Rio Grande Street
Salt Lake City, UT 84101
phone: (385) 269-0203
fax: (801) 821-2872
info@recursion.com
Investor Relations

Connect

LinkedIn
Twitter
Youtube